Last $6.76 USD
Change Today -0.53 / -7.27%
Volume 11.1K
IRIX On Other Exchanges
As of 8:10 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

iridex corp (IRIX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/22/14 - $11.00
52 Week Low
10/28/13 - $5.87
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IRIDEX CORP (IRIX)

Related News

No related news articles were found.

iridex corp (IRIX) Related Businessweek News

No Related Businessweek News Found

iridex corp (IRIX) Details

IRIDEX Corporation develops, manufactures, markets, sells, and services medical laser systems and associated instrumentation for the treatment of the sight-threatening eye diseases worldwide. Its ophthalmology products consist of laser consoles, such as visible (yellow) photocoagulator console, infrared photocoagulator consoles, micropulse enabled consoles, and multi-wavelength laser system configurations. The company also provides ophthalmic delivery devices and other products, such as TxCell scanning laser delivery systems; TruFocus laser indirect ophthalmoscopes; slit lamp adapters; and operating microscope adapters. In addition, it offers EndoProbe, a fiber optic delivery device used for endophotocoagulation, a retinal treatment procedure; G-Probe, a sterile consumable multi-use product used in procedures to treat medically and surgically uncontrolled glaucoma; and DioPexy Probe, a hand-held instrument used in procedures to treat retinal tears. Further, the company provides GreenTip Soft Tip Cannula, a sterile disposable product, which allows surgeons to visualize and access the proximity of the retina while performing a fluid air exchange during a vitrectomy procedure; and MoistAir in-line air humidifier that provides humidified air to the eye during fluid air exchange. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It sells and markets its products through a direct sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.

101 Employees
Last Reported Date: 03/27/14
Founded in 1989

iridex corp (IRIX) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $200.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $284.7K
Vice President of Operations
Total Annual Compensation: $138.5K
Compensation as of Fiscal Year 2013.

iridex corp (IRIX) Key Developments

IRIDEX Corporation Introduce its New Family of Patented Adjustable & Intuitive Extended Reach

IRIDEX Corporation announced that it will introduce its new family of patented Adjustable & Intuitive Extended Reach (A&I XR) laser probes at the annual meeting of the American Academy of Ophthalmology to be held October 18 - 21 at McCormick Place in Chicago. The A&I XR laser probes are used for laser photocoagulation during vitreoretinal procedures. These new devices offer unprecedented uniformity and consistency of treatment using both straight and angled configurations that allow the surgeon to comfortably reach all parts of the anatomy. Vitreoretinal procedures include the management of a variety of conditions that affect the vitreous and retina that lie on the back part of the eye, such as diabetic retinopathy, macular degeneration, retinal detachments or tears and macular holes.

IRIDEX Corporation Receives U.S. Patent for Disposable Micropulse Delivery Device for the Non-Invasive Treatment of Glaucoma

IRIDEX Corporation announced that the United States Patent and Trademark Office granted the company a patent for a new proprietary disposable delivery device. The disposable delivery device, the first of its kind, enables ophthalmologists to administer IRIDEX' proprietary MicroPulse Laser Therapy in a unique and non-invasive way. The new disposable delivery device was developed to address a broad range of glaucoma patients and is planned to be commercially available in the first quarter of 2015. Glaucoma is a cause of adult irreversible blindness. It is estimated that more than 4 million people in the US and approximately 60 million worldwide are afflicted with the disease. It is IRIDEX' opinion that the safety profile of MicroPulse may provide a treatment alternative for patients while also allowing physicians' to use other types of required glaucoma therapies as the disease progresses.

IRIDEX Corporation Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 01:55 PM

IRIDEX Corporation Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 01:55 PM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: William M. Moore, Chairman of the Board, Interim Chief Executive Officer and Interim President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IRIX:US $6.76 USD -0.53

IRIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cutera Inc $9.66 USD -0.26
Ellex Medical Lasers Ltd A$0.30 AUD -0.01
Lutronic Corp 27,150 KRW +3,200
STAAR Surgical Co $10.24 USD -0.24
Synergetics USA Inc $3.46 USD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation IRIX Industry Range
Price/Earnings 43.9x
Price/Sales 1.8x
Price/Book 2.8x
Price/Cash Flow 41.7x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRIDEX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at